Clinical Trial Update: A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tocilizumab for remission-induction and glucocorticoid-sparing therapy in new-onset polymyalgia rheumatica has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Polymyalgia Rheumatica | Phase 3 | Status: COMPLETED